Published in N Engl J Med on January 23, 2014
TB Screening Improves Preventive Therapy Uptake (TB SCRIPT) | NCT04557176
Identifying locations of recent TB transmission in rural Uganda: a multidisciplinary approach. Trop Med Int Health (2015) 2.10
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. PLoS Med (2015) 1.33
Troubles with tuberculosis prevention. N Engl J Med (2014) 1.24
Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci U S A (2014) 1.12
Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev (2014) 1.03
Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. Am J Epidemiol (2015) 0.98
A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med (2014) 0.97
A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med (2014) 0.97
Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet (2015) 0.94
Transforming the fight against tuberculosis: targeting catalysts of transmission. Clin Infect Dis (2014) 0.87
Transformative tools for tackling tuberculosis. J Exp Med (2015) 0.87
Prevalence and correlates of latent tuberculosis infection among employees of a high security prison in Malaysia. Occup Environ Med (2015) 0.85
Trends in silicosis prevalence and the healthy worker effect among gold miners in South Africa: a prevalence study with follow up of employment status. BMC Public Health (2015) 0.84
Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis (2014) 0.84
Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect (2016) 0.82
Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS (2015) 0.82
Prevalence of latent tuberculosis infection and associated risk factors in an urban African setting. BMC Infect Dis (2015) 0.82
Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. BMC Infect Dis (2015) 0.80
A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med (2014) 0.80
Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One (2015) 0.79
Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model. J Acquir Immune Defic Syndr (2014) 0.79
Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. Pediatr Infect Dis J (2015) 0.78
Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses. J Immunol (2016) 0.78
Targeting HIV services to male migrant workers in southern Africa would not reverse generalized HIV epidemics in their home communities: a mathematical modeling analysis. Int Health (2015) 0.78
Molecular epidemiology of Mycobacterium tuberculosis among South African gold miners. Ann Am Thorac Soc (2015) 0.78
Tuberculosis prevention in South Africa. PLoS One (2015) 0.77
Treatment of latent tuberculosis infection induces changes in multifunctional Mycobacterium tuberculosis-specific CD4(+) T cells. Med Microbiol Immunol (2015) 0.76
BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers. Clin Infect Dis (2016) 0.75
Latent Tuberculosis in Health Care Workers Exposed to Active Tuberculosis in a Tertiary Care Hospital in Oman. Oman Med J (2016) 0.75
Clinical Relevance of Nontuberculous Mycobacteria Isolated from Sputum in a Gold Mining Workforce in South Africa: An Observational, Clinical Study. Biomed Res Int (2015) 0.75
The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. BMC Med (2016) 0.75
Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis (2017) 0.75
Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact. Int J Tuberc Lung Dis (2017) 0.75
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS (2016) 0.75
Mycobacterium tuberculosis: 2014 Clinical trials in review. Can J Infect Dis Med Microbiol (2015) 0.75
Mathematical Models of Tuberculosis Reactivation and Relapse. Front Microbiol (2016) 0.75
Mining for answers: Tuberculosis research informs class action sought by gold miners. Nat Med (2016) 0.75
Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. Int J Tuberc Lung Dis (2017) 0.75
Public health implications of changing patterns of recruitment into the South African mining industry, 1973-2012: a database analysis. BMC Public Health (2017) 0.75
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis (2009) 6.96
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med (2007) 6.26
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis (2009) 5.75
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS (2008) 5.26
Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr (2006) 4.81
Evaluation of respondent-driven sampling. Epidemiology (2012) 4.75
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med (2003) 4.67
Latent Mycobacterium tuberculosis infection. N Engl J Med (2015) 4.62
Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial. Lancet (2013) 4.58
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
The Millennium Development Goals: a cross-sectoral analysis and principles for goal setting after 2015 Lancet and London International Development Centre Commission. Lancet (2010) 4.24
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Male circumcision for HIV prevention: from evidence to action? AIDS (2008) 4.11
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
The HIV-associated tuberculosis epidemic--when will we act? Lancet (2010) 3.82
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Biological and behavioural impact of an adolescent sexual health intervention in Tanzania: a community-randomized trial. AIDS (2007) 3.51
How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis (2004) 3.50
Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS (2002) 3.47
New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med (2011) 3.46
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med (2004) 3.45
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (2002) 3.45
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. PLoS Med (2011) 3.25
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS (2007) 3.19
The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine (2006) 3.16
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS (2009) 3.06
Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis (2002) 3.06
A review of self-testing for HIV: research and policy priorities in a new era of HIV prevention. Clin Infect Dis (2013) 3.03
HIV decline in Zimbabwe due to reductions in risky sex? Evidence from a comprehensive epidemiological review. Int J Epidemiol (2010) 2.96
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis (2013) 2.95
AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 2.92
Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med (2007) 2.88
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr (2009) 2.81
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol (2006) 2.81
Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis (2002) 2.80
Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. J Acquir Immune Defic Syndr (2006) 2.77
Undiagnosed HIV infection among adolescents seeking primary health care in Zimbabwe. Clin Infect Dis (2010) 2.74
Uptake of workplace HIV counselling and testing: a cluster-randomised trial in Zimbabwe. PLoS Med (2006) 2.71
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet (2002) 2.64
Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis (2002) 2.60
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS (2010) 2.60
Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. J Clin Microbiol (2004) 2.55
Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS (2008) 2.54
Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis (2004) 2.44
Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis (2008) 2.42
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis (2010) 2.38
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis (2006) 2.29
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS (2007) 2.23
From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med (2007) 2.23
Confronting multidrug-resistant tuberculosis. N Engl J Med (2012) 2.22
Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. J Clin Microbiol (2002) 2.21
HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. AIDS (2007) 2.15
Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA (2007) 2.13
Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials (2007) 2.12
Long-term biological and behavioural impact of an adolescent sexual health intervention in Tanzania: follow-up survey of the community-based MEMA kwa Vijana Trial. PLoS Med (2010) 2.09
Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychol Health Med (2007) 2.08
HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med (2009) 2.07
Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of HIV infection. Clin Infect Dis (2005) 2.06
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr (2010) 2.05
Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A (2008) 2.03
Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ (2010) 2.03
HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis (2010) 2.02